We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $65.26, moving -0.44% from the previous trading session. This change lagged the S&P 500's daily gain of 0.67%. Meanwhile, the Dow gained 0.57%, and the Nasdaq, a tech-heavy index, added 0.61%.
Prior to today's trading, shares of the HIV and hepatitis C drugmaker had lost 9.37% over the past month. This has lagged the Medical sector's gain of 0.38% and the S&P 500's gain of 7.78% in that time.
Investors will be hoping for strength from GILD as it approaches its next earnings release. On that day, GILD is projected to report earnings of $1.90 per share, which would represent year-over-year growth of 8.57%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $6.38 billion, up 13.84% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.95 per share and revenue of $24.19 billion, which would represent changes of +4.83% and +7.74%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for GILD. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 5.17% higher. GILD currently has a Zacks Rank of #3 (Hold).
Investors should also note GILD's current valuation metrics, including its Forward P/E ratio of 9.43. This valuation marks a discount compared to its industry's average Forward P/E of 24.91.
Meanwhile, GILD's PEG ratio is currently 1.73. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.73 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 178, which puts it in the bottom 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $65.26, moving -0.44% from the previous trading session. This change lagged the S&P 500's daily gain of 0.67%. Meanwhile, the Dow gained 0.57%, and the Nasdaq, a tech-heavy index, added 0.61%.
Prior to today's trading, shares of the HIV and hepatitis C drugmaker had lost 9.37% over the past month. This has lagged the Medical sector's gain of 0.38% and the S&P 500's gain of 7.78% in that time.
Investors will be hoping for strength from GILD as it approaches its next earnings release. On that day, GILD is projected to report earnings of $1.90 per share, which would represent year-over-year growth of 8.57%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $6.38 billion, up 13.84% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.95 per share and revenue of $24.19 billion, which would represent changes of +4.83% and +7.74%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for GILD. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 5.17% higher. GILD currently has a Zacks Rank of #3 (Hold).
Investors should also note GILD's current valuation metrics, including its Forward P/E ratio of 9.43. This valuation marks a discount compared to its industry's average Forward P/E of 24.91.
Meanwhile, GILD's PEG ratio is currently 1.73. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.73 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 178, which puts it in the bottom 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.